Diagnostic performance of vascular endothelial growth factor D in severity stratification of pediatric COVID-19 and multisystem inflammatory syndrome in children - Scorecard - MDSpire
Advertisement
Diagnostic performance of vascular endothelial growth factor D in severity stratification of pediatric COVID-19 and multisystem inflammatory syndrome in children
Clinical Scorecard: Evaluating the Role of Vascular Endothelial Growth Factor D in Assessing Severity of Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children
At a Glance
Category
Detail
Condition
Pediatric COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C)
Key Mechanisms
VEGF-D as a biomarker for disease severity, endothelial dysfunction, hypoxia, and pathological angiogenesis.
Target Population
Children with confirmed COVID-19 and MIS-C.
Care Setting
Pediatric clinical settings.
Key Highlights
VEGF-D levels significantly higher in COVID-19 and MIS-C compared to healthy controls.
Clinically relevant cut-off values established: 387.87 pg/mL for severe COVID-19 and 461.96 pg/mL for differentiating MIS-C.
VEGF-D associated with severe hypoxia and elevated inflammatory markers in COVID-19 and MIS-C.
Guideline-Based Recommendations
Diagnosis
Use VEGF-D levels to assess severity in pediatric COVID-19 and MIS-C.
Management
Consider VEGF-D as part of the inflammatory-endothelial profile for patient management.
Monitoring & Follow-up
Monitor VEGF-D levels alongside acute-phase markers and pro-inflammatory cytokines.
Risks
Increased VEGF-D levels correlate with severe disease outcomes.
Patient & Prescribing Data
Children diagnosed with COVID-19 and MIS-C.
VEGF-D may inform treatment strategies based on severity stratification.
Clinical Best Practices
Incorporate VEGF-D measurement in the evaluation of pediatric patients with COVID-19 and MIS-C.
Utilize VEGF-D levels to differentiate between clinical phenotypes of COVID-19.
